Subtopic Deep Dive
Antithrombotic Therapy
Research Guide
What is Antithrombotic Therapy?
Antithrombotic therapy encompasses anticoagulant drugs and reversal agents used to prevent and treat thrombosis in conditions like venous thromboembolism, pulmonary embolism, stroke, and sepsis.
This subtopic focuses on direct oral anticoagulants (DOACs) such as rivaroxaban and apixaban, vitamin K antagonists like warfarin, and agents like drotrecogin alfa for severe sepsis. Key trials demonstrate efficacy in VTE treatment and stroke prevention with bleeding risk trade-offs (Bauersachs 2010; Agnelli et al. 2012). Over 20,000 citations across listed papers highlight clinical trial evidence from NEJM and CHEST.
Why It Matters
Antithrombotic therapy reduces mortality in severe sepsis by 6.1% absolute risk reduction while increasing bleeding risk (Bernard et al. 2001, 6126 citations). Rivaroxaban simplifies VTE treatment over warfarin, improving adherence in outpatient settings (Bauersachs 2010, 3189 citations; Bauersachs et al. 2012, 2318 citations). Apixaban extends VTE prophylaxis with lower bleeding rates than placebo (Agnelli et al. 2012, 1307 citations), guiding guidelines for pregnancy (Bates et al. 2012) and pediatrics (Monagle et al. 2012).
Key Research Challenges
Bleeding Risk Management
Antithrombotics like drotrecogin alfa reduce sepsis mortality but elevate bleeding (Bernard et al. 2001). Rivaroxaban shows noninferiority to standard therapy yet requires monitoring for hemorrhage (Bauersachs 2010). Balancing efficacy and safety remains critical in trials (Agnelli et al. 2012).
Duration of Therapy
Optimal anticoagulation length for idiopathic VTE exceeds three months (Kearon et al. 1999, 1069 citations). Extended apixaban dosing prevents recurrence without excess bleeding (Agnelli et al. 2012). Determining individualized durations challenges clinical practice (Bates et al. 2012).
Special Populations
Therapy in pregnancy and neonates requires tailored dosing due to thrombophilia risks (Bates et al. 2012; Monagle et al. 2012). Pediatric cerebral sinovenous thrombosis shows high neurologic impairment (deVeber et al. 2001). Adapting adult trial data to children persists as a gap.
Essential Papers
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
Gordon R. Bernard, Jean‐Louis Vincent, Pierre‐François Laterre et al. · 2001 · New England Journal of Medicine · 6.1K citations
Treatment with drotrecogin alfa activated significantly reduces mortality in patients with severe sepsis and may be associated with an increased risk of bleeding.
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
Rupert Bauersachs · 2010 · New England Journal of Medicine · 3.2K citations
Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation. (Funded by Bayer Sc...
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Non Renseigné · 2012 · New England Journal of Medicine · 2.3K citations
A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile. (Fun...
Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo
Marie-Luise von Brühl, Konstantin Stark, Alexander Steinhart et al. · 2012 · The Journal of Experimental Medicine · 1.7K citations
Deep vein thrombosis (DVT) is a major cause of cardiovascular death. The sequence of events that promote DVT remains obscure, largely as a result of the lack of an appropriate rodent model. We desc...
VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy
Shannon M. Bates, Ian A. Greer, Saskia Middeldorp et al. · 2012 · CHEST Journal · 1.5K citations
Antithrombotic Therapy in Neonates and Children
Paul Monagle, Anthony K.C. Chan, Neil A. Goldenberg et al. · 2012 · CHEST Journal · 1.4K citations
Apixaban for Extended Treatment of Venous Thromboembolism
Giancarlo Agnelli, Harry R. Büller, Alexander T. Cohen et al. · 2012 · New England Journal of Medicine · 1.3K citations
Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of m...
Reading Guide
Foundational Papers
Start with Bernard et al. (2001) for sepsis mortality reduction and bleeding risks; Bauersachs (2010) for rivaroxaban VTE efficacy; Kearon et al. (1999) for anticoagulation duration evidence.
Recent Advances
Agnelli et al. (2012) on apixaban extension; Bates et al. (2012) on pregnancy; Monagle et al. (2012) on pediatrics.
Core Methods
Randomized noninferiority trials (DOAC vs standard therapy); mouse DVT models (von Brühl et al. 2012); hazard ratio meta-analysis for bleeding-efficacy balance.
How PapersFlow Helps You Research Antithrombotic Therapy
Discover & Search
Research Agent uses searchPapers and citationGraph to map rivaroxaban trials from Bauersachs (2010), linking to 3189 citing papers on DOACs. exaSearch uncovers pregnancy-specific guidelines from Bates et al. (2012), while findSimilarPapers expands to apixaban studies like Agnelli et al. (2012).
Analyze & Verify
Analysis Agent applies readPaperContent to extract hazard ratios from Bernard et al. (2001) sepsis trial, then verifyResponse with CoVe checks claims against raw abstracts. runPythonAnalysis computes meta-analysis of bleeding rates across rivaroxaban papers using pandas, with GRADE grading for evidence quality in VTE trials.
Synthesize & Write
Synthesis Agent detects gaps in reversal strategies for DOACs via contradiction flagging between Weitz et al. (1990) and modern trials. Writing Agent uses latexEditText and latexSyncCitations to draft guidelines citing Kearon et al. (1999), with latexCompile for publication-ready tables and exportMermaid for therapy decision trees.
Use Cases
"Compare bleeding risks in rivaroxaban vs warfarin VTE trials using Python meta-analysis."
Research Agent → searchPapers('rivaroxaban VTE bleeding') → Analysis Agent → readPaperContent(Bauersachs 2010) + runPythonAnalysis(pandas forest plot of HRs) → researcher gets CSV of pooled risk ratios with confidence intervals.
"Draft LaTeX review on apixaban for extended VTE treatment."
Synthesis Agent → gap detection(Agnelli 2012) → Writing Agent → latexEditText(structured abstract) → latexSyncCitations(10 papers) → latexCompile(PDF) → researcher gets compiled review with figure tables.
"Find code for DVT mouse model simulations from thrombosis papers."
Research Agent → citationGraph(von Brühl 2012) → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets validated GitHub repo with monocyte-neutrophil thrombosis simulation code.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ DOAC papers, chaining searchPapers → citationGraph → GRADE grading for efficacy-safety meta-report on rivaroxaban (Bauersachs 2010). DeepScan applies 7-step analysis with CoVe checkpoints to verify bleeding claims in Bernard et al. (2001). Theorizer generates hypotheses on optimal durations from Kearon et al. (1999) trial networks.
Frequently Asked Questions
What is antithrombotic therapy?
Antithrombotic therapy uses anticoagulants like rivaroxaban and apixaban to prevent thrombosis in VTE, PE, and sepsis (Bauersachs 2010; Agnelli et al. 2012).
What are key methods in antithrombotic trials?
Trials compare fixed-dose DOACs to warfarin, measuring recurrent VTE and major bleeding as endpoints (Bauersachs et al. 2012; Kearon et al. 1999).
What are foundational papers?
Bernard et al. (2001, 6126 citations) on drotrecogin alfa for sepsis; Bauersachs (2010, 3189 citations) on rivaroxaban for VTE.
What are open problems?
Optimal durations in special populations like pregnancy (Bates et al. 2012) and reversal for clot-bound thrombin (Weitz et al. 1990).
Research Blood Coagulation and Thrombosis Mechanisms with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Antithrombotic Therapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers